This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Register today

Gain access to the latest results from the Anoro Ellipta head-to-head study

Cardiovascular events, such as cardiac arrhythmias, may be seen after the administration of muscarinic recepter antagonists and sympatho-mimetic agents, including umeclidinium/vilanterol. Therefore, Anoro Ellipta should be used with caution in patients with severe cardiovascular disease. 2

Due to antimuscarinic activity (i.e. a LAMA class effect), Anoro Ellipta and Spiriva should be used with caution in patients with urinary retention or narrow angle glaucoma. 2 3

*At Week 8
**Spiolto is a trade mark of Boehringer Ingelheim
Defined as ≥100 mL increase from baseline in trough FEV1 at Week 8 (p<0.001) vs. Spiolto.

References:

  1. Feldman G.J et al. Adv Ther 2017; 34:doi 10.1007/s12325-017-0626-4
  2. Anoro Ellipta SmPC, 2017
  3. Spiriva SmPC, 2015

ANORO and Ellipta are trademarks of the GSK group of companies.

ANORO Ellipta was developed in collaboration with Innoviva Inc.

Materials supplied by the above-country business unit to LOCs, for localisation must be subject to local Medical and/or Regulatory review and approval prior to external distribution.